Immune dysregulation in RA activates inflammatory pathways and pro-inflammatory cytokines like TNF-α, IL-1, and IL-6, causing synovial hyperplasia and cartilage destruction. RA also impacts cardiovascular health, increasing the risk of CVDs due to systemic inflammation. The NLRP3 inflammasome is a key mediator in RA inflammation, and inhibiting it reduces disease severity. NRF2, a transcription factor, downregulates NLRP3 and protects joint cells from oxidative stress. Promising NRF2 activators like RTA 408, bardoxolone methyl, sulforaphane, curcumin, and EGCG are in development. This evidence concerns the gene IL1B and rheumatoid arthritis.